CYTK Looks 64.3% Undervalued on GF Value™ Despite Profitability
Cytokinetics Inc (CYTK) saw its stock decline after detailed Phase 3 trial data for Myqorzo was released. The company plans to file an FDA application in Q4 2026. CYTK trades at a high P/S ratio of 136.11, with a GF Value™ suggesting it is 64.3% undervalued. The GF Score™ is 51/100, indicating moderate fundamentals with weak profitability and financial strength. Insiders have sold $43.7M in shares, while 8 gurus hold positions, with mixed activity.
How this was made
The 30-second read
Why it matters
The detailed Phase 3 results reduce the probability of a near‑term commercial launch, increasing short‑term risk.
Market read
New trial data is a material catalyst for CYTK and may influence peer valuations in the cardiac therapeutics space.
What to watch
Insider selling and high P/S ratio suggest financial strain that may limit near‑term upside.
Background
CYTK is a late‑stage biopharma focused on muscle activators, with Myqorzo targeting symptomatic non‑obstructive hypertrophic cardiomyopathy.
Ticker impact
Detailed Phase 3 ACACIA-HCM trial data for Myqorzo was released, providing new efficacy and safety information that could affect the stock price.
Potential further decline of 5‑10% as investors reassess valuation.
Data were presented at a major cardiology congress and published in a top journal, representing the first comprehensive release beyond topline results.
Market effects
Biotech sector may see heightened scrutiny of late‑stage trial data, affecting peers with similar pipelines.
U.S. biotech stocks could face short‑term pressure in Nasdaq trading.
Limited to companies developing cardiac therapeutics; no broad macro impact.
Counterpoint
Despite the data softening, the long‑term upside from a potential label expansion could still justify a buy on valuation.
Key entities
- companyCytokinetics Inc
NASDAQ‑listed biotech developing Myqorzo.
- drugMyqorzo (aficamten)
Allosteric cardiac myosin inhibitor in Phase 3 trials.
